Given the promising survival benefits observed with the combination of TACE and lenvatinib (TACE+LEN) in intermediate-stage HCC patients exceeding the up-to-7 criteria, there is ongoing debate over whether the addition of a PD-1 inhibitor to this regimen is justified. Here, PDCD1 is linked to hepatocellular carcinoma.